Eli Lilly says obesity combo regimen beats tirzepatide alone in Phase 2
Patients on the top dose lost up to 23.3% of their weight against 14.8% on tirzepatide alone, and Phase 3 trials are planned for the end of the year.
Patients on the top dose lost up to 23.3% of their weight against 14.8% on tirzepatide alone, and Phase 3 trials are planned for the end of the year.